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Whole-Exome-Sequencing-Based Discovery
of Human FADD Deficiency
Alexandre Bolze,1 Minji Byun,1,13 David McDonald,2,13 Neil V. Morgan,3,13 Avinash Abhyankar,1,13
Lakshmanane Premkumar,4,13 Anne Puel,5 Chris M. Bacon,6 Fre´de´ric Rieux-Laucat,7 Ki Pang,8
Alison Britland,9 Laurent Abel,1,5 Andrew Cant,2,10 Eamonn R. Maher,3,11 Stefan J. Riedl,4
Sophie Hambleton,2,10 and Jean-Laurent Casanova1,5,12,*
Germline mutations in FASL and FAS impair Fas-dependent apoptosis and cause recessively or dominantly inherited autoimmune lym-
phoproliferative syndrome (ALPS). Patients with ALPS typically present with no other clinical phenotype. We investigated a large,
consanguineous, multiplex kindred in which biological features of ALPS were found in the context of severe bacterial and viral disease,
recurrent hepatopathy and encephalopathy, and cardiac malformations. By a combination of genome-wide linkage and whole-exome
sequencing, we identified a homozygous missense mutation in FADD, encoding the Fas-associated death domain protein (FADD), in the
patients. This FADDmutation decreases steady-state protein levels and impairs Fas-dependent apoptosis in vitro, accounting for biolog-
ical ALPS phenotypes in vivo. It also impairs Fas-independent signaling pathways. The observed bacterial infections result partly from
functional hyposplenism, and viral infections result from impaired interferon immunity. We describe here a complex clinical disorder,
its genetic basis, and some of the keymechanisms underlying its pathogenesis. Our findings highlight the key role of FADD in Fas-depen-
dent and Fas–independent signaling pathways in humans.Germline mutations in FASL1 (MIM 134638) and FAS2,3
(MIM 134637) are genetic etiologies of autoimmune lym-
phoproliferative syndrome (ALPS [MIM 601859]) in hu-
mans. ALPS typically begins in early childhood (median
age at onset: 2 yrs), with lymphadenopathy and/or spleno-
megaly. About half the patients have autoimmune disease,
autoimmune cytopenias being particularly common.4,5
The patients do not suffer from unusually severe infection,
unless they are on immunosuppressive treatment,4 and
display no overt developmental phenotype. We investi-
gated the molecular basis of a condition affecting at least
four members of an extended consanguineous kindred
of Pakistani origin (Figure 1A) with biological features of
ALPS (high-circulating CD4CD8TCRabþ T-cell [DNT]
counts, and elevated IL-10 and FasL serum levels), no clin-
ical features of ALPS, a complex infectious phenotype with
both viral and bacterial infections, and congenital cardio-
vascular malformations (Table 1 and Table S1 available on-
line). This study was approved by the local institutional
review board. Written informed consent for participation
in the study was obtained from all patients and family
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The AmericanThe affected children suffered from recurrent, stereotyp-
ical episodes of fever, encephalopathy, and mild liver
dysfunction (modestly elevated transaminases without
cholestasis, metabolic derangement, or synthetic defects),
sometimes accompanied by generalized seizures that were
difficult to control. Episodes lasted several days, sometimes
requiring intensive care, and cranial imaging in three
patients (P1, P3, and P4 [IV.2, IV.4, and IV.5 in Figure 1])
suggested atrophy, despite subsequent recovery in two of
these patients (P1 and P3). For some of the episodes, it
was possible to identify a viral trigger: varicella zoster virus
(VZV), measles mumps rubella (MMR) attenuated vaccine,
parainfluenza virus, and Epstein-Barr virus (EBV). The
index case, P3 (IV.4 in Figure 1), died at the age of 4 yrs,
during such an episode. In addition, fatal invasive pneu-
mococcal disease occurred in two children (P1 and P2
[IV.2 and IV.3 in Figure 1]), and Howell-Jolly bodies were
detected in the two remaining patients (P3 and P4 [IV.4
and IV.5 in Figure 1]), despite the presence of a spleen
(indicating functional hyposplenism).6–8 This clinical
syndrome has never before been described (no MIM
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Figure 1. Characterization of an Inherited FADD Mutation
(A) Pedigree of the Pakistani family. Black symbols indicate patients. Gray symbols indicate siblings in the parents’ generation who died
early in childhood with clinical symptoms related to the disorder observed in P1–P4. Clinical information was incomplete for these
members of the parents’ generation. Haplotypes of FADD are indicated: M stands for c.315T>G, and WT for the wild-type allele.
(B) Schematic diagram of FADD protein showing the death effector domain (DED) and the death domain (DD). The location correspond-
ing to the mutation is indicated by an arrow, and the predicted amino acid substitution is shown.
(C) Evolutionary conservation of the FADD region containing amino acid residue C105 (indicated by the arrow).
(D) FADD immunoblot in primary fibroblasts and EBV-B cells from patients and controls. Experiments were carried out with two
different antibodies: a mouse monoclonal antibody against the C terminus of FADD (#610399, BD Biosciences) and a rabbit polyclonal
antibody against the residues surrounding Ser194 in human FADD (#2782, Cell Signaling). Similar results were obtained with both anti-
bodies. GAPDH was used as a loading control. A representative blot with the monoclonal antibody is shown (n ¼ 6).
(E and F) FADD protein levels in primary fibroblasts (E) and EBV-B cells (F) determined on the basis of the intensity of the signal on
immunoblots and normalized with respect to GAPDH levels. A mean of six experiments is shown. Error bars indicate the SEM.
(G and H) Effect of the C105W mutation on the stability of FADD DD folding and the Fas-FADD complex. (G) Differential scanning
calorimetry (DSC) analysis of WT and C105W His6-FADD DD proteins. (H) Fas-FADD complex stability assay. The retention of FADD
DD (WTor C105W) with immobilized His6-Fas DD was assessed with various concentrations of NaCl, as previously described
19 (E: imid-
azole elution of remaining complex after the final NaCl concentration).
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Table 1. Clinical Features of Four Patients in the Family
Patient P1 P2 P3 P4
Gender male female female female
Cardiovascular
malformation
none none yes (pulmonary
atresia) þ
ventricular
septal defect
yes (L-sided SVC
draining to
left atrium)
Functional
hyposplenism
spleen size NA normal normal normal
Howell-Jolly bodies NA NA yes yes
invasive pneumococcal
infection
yes (meningitis,
4 mo)
yes (septicemia,
14 mo)
noa noa
Features of
febrile episodes
documented viral trigger VZV VZV, HHV6 MMR vaccine,
astrovirus,
parainfluenza
virus 2, EBV
encephalopathy yes yes yes yes
seizures yes yes yes yes
liver dysfunction (maximal
ALT, IU/L)
yes (NA) yes (NA) yes (1042) yes (383)
ALPS phenotype autoimmune disease no no no no
presence of autoantibodies NA NA nob yesb
(antierythrocyte
antibodies
intermittently
present)
lymphadenopathy or
splenomegaly
no no no no
percentage of
CD4CD8TCRabþ T cells
NA NA NA 7.8
lymphocyte apoptosis NA NA NA impaired
serum FasL NA NA NA high
serum IL-10 NA NA NA high
CNS outcome neurodevelopmental
progress
NA within normal
limits
within normal
limits
within normal
limits
cerebral atrophy
on CT/MRI (age)
yes (4 mo) NA yes (3 mo) mild (5 mo) þ
increased
at 2.5 yr þ spotty
calcification of
subcortical
white matter
Liver histology NA mild chronic
portal
inflammation
with bridging
fibrosis
NA mild chronic portal
inflammation with
mild fibrosis
Follow-up data died at 4 mo died at 14 mo died at 4 yr
and 4 mo.
alive and currently
2 yr and 9 mo.
Abbreviations are as follows: ALT, alanine transaminase; FasL, Fas ligand; HHV6, Human Herpesvirus Six; IL-10, interleukin 10; NA, not assessed.
a On antibacterial prophylaxis from early infancy.
b Autoantibody screen including antinuclear, anti-smooth muscle, antimitochondrial, and anti-gastric parietal cell antibodies, direct antiglobulin test.members had died in childhood, two with ‘‘epilepsy’’ and
two from infection (pneumonia and measles, respectively)
(data not shown), suggesting that there may have been up
to nine patients with this disorder in these two generations
of this kindred.
We hypothesized that this syndrome would segregate as
an autosomal-recessive trait. We investigated its geneticThe Americanetiology, by combining genome-wide linkage analysis
by homozygosity mapping with whole-exome sequenc-
ing.9–11 For the linkage analysis, we genotyped three
affected patients (P2, P3, and P4), their parents (III.1,
III.2, III.3, and III.4), and one healthy sibling (IV.1) with
the Affymetrix 500K SNPArray or the Affymetrix 6.0 Array.
No material was available for P1. Homozygous regionsJournal of Human Genetics 87, 873–881, December 10, 2010 875
were detected with the HomozygosityMapper genome
browser. Two regions (> 1 Mb) were homozygous in the
three affected patients and heterozygous in other members
of the family: an 8Mb region on chromosome 11 (between
rs4930243 and rs7926553; bp position: g.68,499,874–
g.76,470,079; hg18, NCBI 36.1) and a 9Mb region on chro-
mosome 18 (between rs9959449 and rs12327522; bp posi-
tion: g.60,703,632–g.70,387,399; hg18, NCBI 36.1). The
regions were further confirmed by typing microsatellite
markers (Figure S1).
In parallel to the linkage analysis, we sequenced the
exome of P3 with the SureSelect Human All Exon Kit (Agi-
lent Technologies). The sequences obtained were aligned
to the reference genome (hg18 build) with the Burrows-
Wheeler Aligner. Three open-source packages were used
for downstream processing and variant calling: the
Genome Analysis Toolkit (GATK),12 SAMtools,13 and Pic-
ard Tools. Substitution calls weremadewith the GATKUni-
fiedGenotyper. All calls with a read coverage < 43 and
a phred-scaled SNP quality of < 30 were filtered out. All
the variants were annotated with SeattleSeq SNP Annota-
tion. In total, we identified 23,146 variations. Of these,
67 variants were found in the chromosome 11 candidate
region, and 14 variants were found in the chromosome
18 candidate region (Table S2). Comparisons with the
NCBI dbSNP build 129, the 1000 Genomes Project data-
base, and our in-house database (composed of 70 exomes)
identified only one nonsynonymous variant that had
not been reported before and mapped to the chromosome
11 region. No previously unreported nonsynonymous
variant mapping to the linked region on chromosome
18 was identified. The variant identified was a missense
homozygous c.315T>G in exon 2 of FADD (NM_003824.
3, MIM 602457) that changes cysteine at amino acid posi-
tion 105 to tryptophan, p.C105W (referred to as C105W
hereafter) (Figure 1B and Figure S2). Cysteine at amino
acid position 105 is highly conserved throughout evolu-
tion (Figure 1C). We validated this variant by Sanger
sequencing on genomic DNA from peripheral blood and
on cDNA from EBV-transformed B cells (EBV-B). This
variant segregated with the disease status in all family
members examined (Figure 1A) and was not found in
282 Pakistani controls, suggesting that it is not an irrele-
vant polymorphism.
FADD was first described as an adaptor protein interact-
ing with the apoptosis-inducing surface receptor Fas.14
It has since been shown to interact with various partners
and to participate in many other cellular processes, such
as autophagy, inflammation, innate immunity, cell prolif-
eration, and tumor development.15–18 Thus, we hypothe-
sized that the FADD mutation was responsible for the
complex clinical phenotype of the affected individuals.
To test this hypothesis, we assessed the expression of
FADD mRNA levels in EBV-B cells by quantitative RT-
PCR. We found that FADD mRNA levels in the EBV-B cells
from P3 (C105W/C105W) were similar to those in the
EBV-B cells from IV.1 (WT/WT) (data not shown).876 The American Journal of Human Genetics 87, 873–881, DecembHowever, FADD protein levels were clearly lower in pri-
mary fibroblasts from P4 (~16%) than in primary fibro-
blasts from a healthy control (Figures 1D and 1E). Simi-
larly, FADD protein levels were lower in the EBV-B cells
from P3 (~21%) and III.1 (WT/C105W) (~62%) than in
the EBV-B cells from IV.1 (Figures 1D and 1F). Residue
C105 is located in alpha-helix 1 of the FADD death domain
(DD), at the interface of the Fas-FADD complex.19 We
tested the effect of the C105W mutation on FADD folding
stability and Fas-FADD interaction with recombinant Fas
DD and FADD DD proteins. The C105W mutant protein
was folded, as shown by differential scanning calorimetry
(DSC), but the folding stability of the mutant protein
was lower than that of WT FADD, by ~10C (Figure 1G).
We then assessed the effect of the mutation on Fas-FADD
complex stability by using a gel copurification assay in
the presence of increasing concentrations of NaCl (Fig-
ure 1H). Binding levels for C105W FADD and Fas were
clearly lower than those for WT FADD, suggesting that
the primary Fas-FADD complex was less stable. Thus, the
C105W mutation in FADD strongly decreases steady-state
protein levels and impairs the interaction of the residual
FADD protein with Fas.
FADD forms a critical bridge between the death receptor
Fas and caspase-8 (MIM 601763), in a multimolecular
array known as the death-inducing signaling complex
(DISC).20,21 We therefore studied Fas-induced apoptosis in
the patients’ cells. Phytohemagglutinin-stimulated periph-
eral-blood lymphocytes (PHA blasts) from P4 displayed
impaired apoptosis (viability >50% higher than for con-
trols) when challenged with cross-linked Fas ligand (FasL),
similar to Fas-deficient cells (Figure 2A). In addition, EBV-B
cells from P3 displayed impaired apoptosis when Fas was
crosslinked with agonistic Fas-specific antibody (Apo1.3)
(Figure 2B). In keeping with this finding, investigations
of the surviving patient P4 revealed several features classi-
cally associated with ALPS due to Fas2,3 or FasL1 deficiency
andmore rarely associated with deficiencies of caspase-8 or
caspase-10 (MIM 601762).4,22,23 P4 displayed an expan-
sion of the population of mature CD4CD8TCRabþ
T cells (DNT) in peripheral blood, as well as elevated serum
levels of IL-10 and soluble FasL (Table 1 and Figures 2C and
2D).24,25 Our data confirm that the FADD C105W variant
impairs apoptotic function both in vitro and in vivo,
resulting in biological features of ALPS despite the lack of
clinically evident autoimmunity or lymphoproliferation
(although P4 did have transiently detectable antierythro-
cyte autoantibodies and P2, P3, and P4 displayed periph-
eral lymphocytosis [Table S1]). T cell proliferation in
response to various stimuli was normal (Figure 2E), in
contrast with findings for caspase-8 deficient individuals22
and mice with FADD deficiency specific to T or B cells.26
A recent study in mice suggested that FADD deficiency
may decrease T cell proliferation as a result of an excess
of necroptosis.16 To examine whether C105Waffected nec-
roptosis, we added an inhibitor of necroptosis, necrostatin
1, to CD3- and CD28-stimulated proliferation assays.er 10, 2010
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Figure 2. Characterization of the ALPS Phenotype
(A) PHA blasts from normal volunteers (Ctrls), patient P4, and a heterozygous Fas-deficient patient were stimulated with recombinant
FasL (r-FasL), and cell viability was analyzed. The proportion of live cells in the presence of r-FasL is displayed as a percentage of live cells
in the presence of enhancer alone, for each sample. Error bars indicate the SEM.
(B) EBV-B cells from P3, IV.1, and a Fas-deficient patient were treated with an antibody against Fas (Apo-1.3), in the presence of rabbit
anti-mouse Ig (Ramig), for 6 hr and analyzed for early apoptosis. The percentage of cells that were apoptotic was calculated as the
percentage of cells positive for AnnexinV and negative for propidium iodide staining. NS indicates that the cells were incubated with
Ramig only. A mean of three independent experiments is shown. Error bars indicate the SEM.
(C) FasL levels in the serum of P4 and eight healthy controls (Ctrls). Error bars indicate the SEM.
(D) IL-10 levels in the serum of P4 and eight healthy controls. IL-10 values were normalized with respect to the mean of the control
samples. Error bars indicate the SEM.
(E) Proliferation assay. Proliferative responses to various stimuli (PHA, 5 mg/ml; IL-2, 500 U/ml; concanavalin A, 5 mg/ml; anti-CD3
[OKT3], 0.1 mg/ml; PMA, 50 ng/ml; ionomycin, 0.1 mg/ml). P3 and P4 responded similarly in comparison to the two controls, C1 and C2.Necrostatin-1 did not affect proliferative responses in this
system (Figure S3).
The laboratory findings for the FADD-deficient patients
were typical of ALPS, but clinical presentation was domi-
nated by features absent from classical ALPS, leading to
early death. These features included invasive pneumo-
coccal disease (IPD), which killed both P1 and P2. Neither
P3 nor P4 suffered from IPD, probably because they were
on antibacterial prophylaxis from early infancy, but abnor-
mally high counts of Howell-Jolly bodies were seen on
their blood smears. The identification of Howell-Jolly
bodies on peripheral-blood smears is themost reliable indi-
cator of impaired splenic phagocyte function (including
functional or anatomical asplenia).6–8 Moreover, asplenia
(MIM 271400 and MIM 208530)—whether anatomical or
functional, congenital or acquired—has frequently been
associated with a strong predisposition to infections by
encapsulated bacteria, such as IPD, in particular.6–8,27 For
example, we showed that 15 of 20 patients with isolated
congenital asplenia (ICA) suffered from invasive bacte-
rial infections, caused mostly by Streptococcus pneumoniae
(61%).27 Finally, B cell responses to vaccine antigensThe Americanappeared to be intact in the patients (Table S1), ruling
out other known causes of IPD.28 These observations
suggest that functional hyposplenism underlies IPD in
FADD-deficient patients.
In addition to IPD, FADD-deficient patients suffered
from recurrent episodes of encephalopathy and liver
dysfunction with fever, which were sometimes triggered
by viral infection (Table 1). Previous studies in mouse
embryonic fibroblasts (MEFs) suggested that FADD plays
a crucial role in type I interferon (IFN) -dependent antiviral
immunity.15,29 We therefore tested the hypothesis that the
unusually severe illnesses associated with viral infections
in FADD-deficient patients might be due to an impaired
type I IFN-dependent antiviral response, by assessing the
antiviral effect of IFN-a in vesicular stomatitis virus
(VSV)-infected P3 and IV.1 EBV-B cells. STAT1-deficient
EBV-B cells, lacking a key type-I-IFN-responsive path-
way,29–31 were included as controls. Prior treatment with
IFN-a protected both P3 and IV.1 cells from VSV-induced
cell death until 36 hr after infection (Figure 3A). However,
IFN-a-treated P3 cells eventually succumbed to VSV infec-
tion, whereas IFN-a-treated IV.1 cells remained protectedJournal of Human Genetics 87, 873–881, December 10, 2010 877
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Figure 3. Impaired Antiviral Immunity
(A) EBV-B cells from P3, IV.1, and a STAT1-deficient patient were
infected with VSV at a multiplicity of infection (MOI) of 1, with
or without prior treatment with 100 IU/ml of IFN-a for 24 hr.
Cell mortality was assessed by measuring the amount of LDH
released into the medium. For STAT1-deficient cells, results are
shown only until 36 hr after infection because of high levels of
spontaneous LDH release at later time points. A mean of three
independent experiments is shown. Error bars indicate the SEM.
(B) EBV-B cells from P3, IV.1, and a STAT1-deficient patient were
either left untreated (NT, bars in white) or treated with 100 IU/ml
IFN-a for 24 hr (IFN-a, bars in black), prior to infection with VSV
at aMOI of 0.1, and were harvested 48 hr after infection. VSV titers
(TCID50,ml) were determined on Vero cells. Amean of three inde-
pendent experiments is shown. Error bars indicate the SEM.
(C) EBV-B cells from P3 or IV.1 were infected with VSV at a MOI of
10. Cellswere harvested at the indicated timepoints, and total RNA
was extracted. IFN-b and IRF7 mRNA levels were determined by
quantitative RT-PCR. Threshold cycles normalized with respect to
those of GUS (DCT) are plotted as 2
DCT. A mean of three indepen-
dent experiments is shown. Error bars indicate the SEM.
878 The American Journal of Human Genetics 87, 873–881, Decembuntil 60 hr after infection (Figures 3A and 3B). These results
suggest that the IFN-a-responsive pathway is intact but
that the positive feedback of IFN signaling is impaired
in FADD-deficient cells. Interferon regulatory factor 7
(IRF7), induced by autocrine type I IFNs, is known to
play a critical role in the positive feedback of IFN signaling,
by inducing IFN-a gene family members. We found that
the induction of IRF7 in response to VSV infection was
impaired in P3 cells, despite levels of IFN-b induction
similar to those in IV.1 cells (Figure 3C). These data provide
a molecular basis for the increase in susceptibility to viral
diseases in FADD-deficient patients.
By contrast, we can only speculate about the mecha-
nisms underlying the developmental abnormalities within
this kindred. P3 displayed pulmonary atresia (MIM
178370) and P4 had a left-sided superior vena cava (SVC)
draining into the left atrium, both of which are rare as
sporadic defects and were probably caused by FADD insuf-
ficiency. Indeed, mice with a null mutation in FADD are
not viable because of embryonic defects, including cardiac
abnormalities, such as thinning of the ventricular myocar-
dium.32 Moreover, FADD expression in mice, at embryonic
day 11.5, is detected not only in the myocardium but also
in the brain, liver, and developing vertebrae.32 Spinal
anatomy appeared normal in all FADD-deficient patients,
but hepatic and cerebral dysfunctions were clearly key
elements of the disease phenotype. Cerebral atrophy was
observed in P1, P3, and P4 at a very early age and appeared
to be progressive in P4 (scan images in Figure S4), despite
continuing neurodevelopment (Table 1). This, and the
mild portal fibrosis observed on liver biopsy in two
patients (Figures 4J–4L), should be considered as sequelae
of FADD deficiency. Finally, FADD seems to be important
for the development of a functional spleen in humans, as
demonstrated by the presence of Howell-Jolly bodies—
the hallmark of a lack of splenic function—in the blood
smears of P3 and P4.7,8 In P2, a limited postmortem exam-
ination of lymph nodes, spleen, and thymus revealed no
histological features of ALPS or other lymphoid tissue
abnormalities (Figure 4). However, the spleen showed
an expanded, congested red pulp containing increased
neutrophils, consistent with sepsis. Moreover, the normal
cord-sinus architecture of the red pulp was not readily
apparent; reticulin deposition appeared disordered, nor-
mal sinusoidal ‘‘barrel hoop’’ fibers were not identified,
and macrophages appeared haphazardly arranged (Figures
4C–4I). Examination of spleen histology in other affected
individuals is unlikely to be possible, thus precluding firm
conclusions regarding the relationship between human
FADD deficiency and disordered red pulp microarchitec-
ture. The prominence but incomplete penetrance of
cardiac, cerebral, hepatic, and splenic abnormalities in the
clinical phenotype strongly suggests the existence of
organ-specific effects of FADD deficiency worthy of further
study in suitably designed mouse models.
In conclusion, we have described the clinical features of
an autosomal-recessive inherited disorder with biologicaler 10, 2010
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Figure 4. Histopathology of P2 and P4
(A–K) postmortem histopathology of P2 at 14 months.
(A) Normal thymic architecture; increased cortical tingible body macrophages consistent with a stress response (P2, hematoxylin and
eosin [H&E] stain, original magnification 3 100).
(B) Normal-appearing reactive lymph node with follicular hyperplasia (P2, H&E stain, original magnification 3 40).
(C) Low-power view of the spleen showing expanded, congested red pulp with relatively reduced white pulp (P2, H&E stain, original
magnification 3 20).
(D) White pulp nodule containing a follicle with a reactive germinal centre, but no marginal zone hyperplasia, arising from a periarter-
iolar lymphoid sheath (P2, H&E stain, original magnification 3 200).
(E) Immunohistochemistry for CD3 shows a normal distribution of CD3-positive T cells in a white pulp nodule (P2, Ventana Benchmark
XT immunostainer, monoclonal antibody LN10, original magnification 3 100).
(F) Immunohistochemistry for CD20 shows a normal distribution of CD20-positive B cells in a white pulp nodule (P2, Ventana Bench-
mark XT immunostainer, monoclonal antibody L26, original magnification 3 100).
(G) Congested, disorganized red pulp containing increased neutrophils consistent with sepsis (P2, H&E stain, original magnification 3
400).
(H) Disorganized reticulin staining pattern of splenic red pulp. Inset: ‘‘barrel hoop’’ arrangement of sinusoidal reticulin fibers in a normal
control spleen (P2, Gordon and Sweet’s reticulin stain, original magnification 3 400).
(I) Immunohistochemistry for CD68 shows a haphazard arrangement of macrophages in the splenic red pulp. Inset: orderly distribution
of cordal macrophages in a normal control spleen (P2, Ventana Benchmark XT immunostainer, monoclonal antibody PG-M1, original
magnification 3 400).
(J) Liver showing portal-portal linkage and expansion of portal tracts by amoderate chronic inflammatory cell infiltrate without interface
activity (P2, H&E stain, original magnification 3 100).
(K) Sirius red staining of liver shows collagen deposition (red) within portal-portal bridges. Elastin could also be demonstrated (not
shown), consistent with established portal-portal fibrosis (P2, Sirius red and Fast green stain, original magnification 3 100).
(L) Histopathology of P4 at 22 months. The liver shows mild expansion of portal tracts by a chronic inflammatory cell infiltrate but no
bridging fibrosis (H&E stain, original magnification 3 200).features of ALPS, susceptibility to bacterial and viral infec-
tions, and developmental abnormalities. Furthermore,
we have determined its genetic etiology, which results inThe AmericanFADD deficiency in the affected children, by genome-
wide linkage analysis and whole-exome sequencing.
Finally, we have dissected the molecular mechanisms ofJournal of Human Genetics 87, 873–881, December 10, 2010 879
disease for several aspects of this phenotype, including
bacterial susceptibility (functional hyposplenism), viral
susceptibility (impaired IFN immunity), and features of
ALPS (impaired Fas-dependent apoptosis). Other pheno-
types, particularly those of a developmental nature,
remain unexplained but are probably due to the disruption
of Fas-independent pathways, given that they were not
documented in Fas-deficient patients. These unanticipated
findings highlight the power of exome sequencing used
in combination with genome-wide linkage analysis
within consanguineous families.9–11,33 We anticipate rapid
advances in molecular medicine,5,9 facilitated by this
strategy, in the coming years.Supplemental Data
Supplemental Data include four figures and two tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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